Business
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
Safety and pharmacokinetic data in healthy volunteers support ongoing clinical development AT-752 is a novel, orally administered, direct-acting antiviral in
About this update from Atea Pharmaceuticals, Inc.
[{"type":"text","content":"Safety and pharmacokinetic data in healthy volunteers support ongoing clinical development AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development with a Fast Track designation from the U.S. Food and Drug Administration for treatment of dengue Dengue is endemic in more than 100 countries putting greater than half the world’s population at-risk for this mosquito-borne viral disease BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented a poster highlighting favorable AT-752 Phase 1 clinical data for the treatment of dengue fever at the American Society of Tropical Medicine & Hygiene (ASTMH) 2022 Annual Meeting in Seattle, Washington. The poster #1358, titled “Safety, tolerability, and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus: results from a Phase 1, first-in-human, dose-escalation study,” was presented by Xiao-Jian Zhou, PhD, Executive Vice President of Early Stage Development at Atea Pharmaceuticals. “Dengue is the most prevalent mosquito-borne virus and despite its alarming increase over the last two decades, there are no direct-acting antiviral treatments available,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. “These data demonstrate that AT-752 was well tolerated up to the highest dose tested and rapidly achieved plasma levels above the in vitro EC90. Based on these data, we anticipate that AT-752 may have the potential to rapidly inhibit dengue virus replication across all serotypes (1-5). In addition, AT-752 exhibited no pharmacokinetic sensitivity across varying ethnic populations participating in the trial.” “Importantly, these results support our advancement of two proof-of-concept studies to demonstrate AT-752’s safety and efficacy for the treatment and potential prophylaxis of dengue,” continued Dr. Sommadossi. Atea is currently conducting two AT-752 clinical studies. The first study is a global, randomized, double-blind, placebo-controlled Phase 2 trial in adult patients with dengue virus infection. The study is designed to evaluate the antiviral activity, safety and pharmacokinetics (PK) of multiple doses of AT-752 in areas where dengue is endemic. The second study is a human ch...